Serena Hung

907 total citations
22 papers, 693 citations indexed

About

Serena Hung is a scholar working on Pathology and Forensic Medicine, Neurology and Oncology. According to data from OpenAlex, Serena Hung has authored 22 papers receiving a total of 693 indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Pathology and Forensic Medicine, 10 papers in Neurology and 10 papers in Oncology. Recurrent topics in Serena Hung's work include Multiple Sclerosis Research Studies (19 papers), Peripheral Neuropathies and Disorders (9 papers) and Polyomavirus and related diseases (9 papers). Serena Hung is often cited by papers focused on Multiple Sclerosis Research Studies (19 papers), Peripheral Neuropathies and Disorders (9 papers) and Polyomavirus and related diseases (9 papers). Serena Hung collaborates with scholars based in United States, Germany and Canada. Serena Hung's co-authors include Douglas L. Arnold, Peter A. Calabresi, Ying Zhu, Aaron Deykin, Ali Seddighzadeh, Alexey Boyко, Laura J. Balcer, Jean Pelletier, Bernd C. Kieseier and Shifang Liu and has published in prestigious journals such as Neurology, The Lancet Neurology and Movement Disorders.

In The Last Decade

Serena Hung

22 papers receiving 680 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Serena Hung United States 11 469 330 206 173 68 22 693
Marc Coustans France 10 689 1.5× 338 1.0× 197 1.0× 249 1.4× 98 1.4× 10 878
Shalom Haggiag Italy 17 376 0.8× 260 0.8× 85 0.4× 131 0.8× 82 1.2× 51 710
Héctor Perkal Spain 14 617 1.3× 286 0.9× 205 1.0× 163 0.9× 109 1.6× 19 873
Bruno Brochet France 6 735 1.6× 398 1.2× 190 0.9× 105 0.6× 55 0.8× 12 872
T. Arbizu Spain 15 563 1.2× 216 0.7× 165 0.8× 161 0.9× 154 2.3× 28 745
D. Franciotta Italy 11 518 1.1× 382 1.2× 193 0.9× 92 0.5× 131 1.9× 16 685
Jessica Sagen United States 7 548 1.2× 578 1.8× 200 1.0× 50 0.3× 77 1.1× 13 790
J. C. Alvarez‐Cermeño Spain 12 391 0.8× 262 0.8× 127 0.6× 108 0.6× 119 1.8× 20 529
E. Mauch Germany 11 393 0.8× 251 0.8× 71 0.3× 219 1.3× 69 1.0× 27 603
Vanessa Daccach Marques Brazil 14 330 0.7× 263 0.8× 87 0.4× 44 0.3× 58 0.9× 32 522

Countries citing papers authored by Serena Hung

Since Specialization
Citations

This map shows the geographic impact of Serena Hung's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Serena Hung with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Serena Hung more than expected).

Fields of papers citing papers by Serena Hung

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Serena Hung. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Serena Hung. The network helps show where Serena Hung may publish in the future.

Co-authorship network of co-authors of Serena Hung

This figure shows the co-authorship network connecting the top 25 collaborators of Serena Hung. A scholar is included among the top collaborators of Serena Hung based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Serena Hung. Serena Hung is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Bryś, Mirosław, Laura Fanning, Serena Hung, et al.. (2019). Randomized phase I clinical trial of anti–α‐synuclein antibody BIIB054. Movement Disorders. 34(8). 1154–1163. 139 indexed citations
2.
Newsome, Scott D., Thomas F. Scott, Douglas L. Arnold, et al.. (2018). Long-term outcomes of peginterferon beta-1a in multiple sclerosis: results from the ADVANCE extension study, ATTAIN. Therapeutic Advances in Neurological Disorders. 11. 1277012711–1277012711. 17 indexed citations
3.
4.
Newsome, Scott D., Bernd C. Kieseier, Douglas L. Arnold, et al.. (2016). Subgroup and sensitivity analyses of annualized relapse rate over 2 years in the ADVANCE trial of peginterferon beta-1a in patients with relapsing-remitting multiple sclerosis. Journal of Neurology. 263(9). 1778–1787. 14 indexed citations
5.
Scott, Thomas F., Bernd C. Kieseier, Scott D. Newsome, et al.. (2016). Improvement in relapse recovery with peginterferon beta-1a in patients with multiple sclerosis. Multiple Sclerosis Journal - Experimental Translational and Clinical. 2. 2451096612–2451096612. 11 indexed citations
6.
White, Joleen T., Scott D. Newsome, Bernd C. Kieseier, et al.. (2016). Incidence, characterization, and clinical impact analysis of peginterferon beta1a immunogenicity in patients with multiple sclerosis in the ADVANCE trial. Therapeutic Advances in Neurological Disorders. 9(4). 239–249. 25 indexed citations
7.
Newsome, Scott D., Bernd C. Kieseier, Shifang Liu, et al.. (2016). Peginterferon beta-1a reduces disability worsening in relapsing–remitting multiple sclerosis: 2-year results from ADVANCE. Therapeutic Advances in Neurological Disorders. 10(1). 41–50. 9 indexed citations
8.
9.
Seddighzadeh, Ali, Serena Hung, Krzysztof Selmaj, et al.. (2014). Single-use autoinjector for peginterferon-β 1a treatment of relapsing-remitting multiple sclerosis: safety, tolerability and patient evaluation data from the Phase IIIb ATTAIN study. Expert Opinion on Drug Delivery. 11(11). 1713–1720. 12 indexed citations
10.
Calabresi, Peter A., Douglas L. Arnold, Laura J. Balcer, et al.. (2014). Pegylated interferon beta-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study. The Lancet Neurology. 13(7). 657–665. 288 indexed citations
11.
Hu, Xiao, Ali Seddighzadeh, Ying Zhu, et al.. (2014). Pharmacokinetics, pharmacodynamics, and safety of peginterferon beta‐1a in subjects with normal or impaired renal function. The Journal of Clinical Pharmacology. 55(2). 179–188. 8 indexed citations
12.
Hu, Xiao, Yue Cui, Joleen T. White, et al.. (2014). Pharmacokinetics and pharmacodynamics of peginterferon beta‐1a in patients with relapsing‐remitting multiple sclerosis in the randomized ADVANCE study. British Journal of Clinical Pharmacology. 79(3). 514–522. 16 indexed citations
13.
Kieseier, Bernd C., Thomas F. Scott, Scott D. Newsome, et al.. (2014). Peginterferon Beta-1a May Improve Recovery Following Relapses: Data from the Pivotal Phase 3 ADVANCE Study in Patients with Relapsing-Remitting Multiple Sclerosis (S4.003). Neurology. 82(10_supplement). 1 indexed citations
14.
Kieseier, Bernd C., Thomas F. Scott, Scott D. Newsome, et al.. (2014). Peginterferon Beta-1a May Improve Recovery Following Relapses: Data from the Pivotal Phase 3 ADVANCE Study in Patients with Relapsing-Remitting Multiple Sclerosis (I7-1.002). Neurology. 82(10_supplement). 1 indexed citations
15.
Kieseier, Bernd C., Douglas L. Arnold, Laura J. Balcer, et al.. (2014). Peginterferon beta-1a in multiple sclerosis: 2-year results from ADVANCE. Multiple Sclerosis Journal. 21(8). 1025–1035. 84 indexed citations
16.
Arnold, Douglas L., Peter A. Calabresi, Bernd C. Kieseier, et al.. (2014). Effect of peginterferon beta-1a on MRI measures and achieving no evidence of disease activity: results from a randomized controlled trial in relapsing-remitting multiple sclerosis. BMC Neurology. 14(1). 240–240. 38 indexed citations
17.
18.
19.
20.
Hu, Xiheng, et al.. (2012). PEGylated Interferon Beta-1a Pharmacokinetics, Pharmacodynamics, and Safety in Subjects with Normal or Impaired Renal Function (P06.165). Neurology. 78(Meeting Abstracts 1). P06.165–P06.165. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Marc Coustans Breakdown of academic impact, for papers by Shalom Haggiag Breakdown of academic impact, for papers by Héctor Perkal Breakdown of academic impact, for papers by Bruno Brochet Breakdown of academic impact, for papers by T. Arbizu Breakdown of academic impact, for papers by D. Franciotta Breakdown of academic impact, for papers by Jessica Sagen Breakdown of academic impact, for papers by J. C. Alvarez‐Cermeño Breakdown of academic impact, for papers by E. Mauch Breakdown of academic impact, for papers by Vanessa Daccach Marques
Rankless by CCL
2026